Selinexor, an inhibitor of the nuclear Exportin 1 (XPO1), decreases the expression of the FA/BRCA and NF-kB pathway genes, reduces melphalan-induced monoubiquitination of FANCD2, and overcomes the resistance of the MM cell lines to melphalan [162]. Here, XPO1 is linked to Miyoshi myopathy.